Technical Momentum Gains Strength
Novartis India’s technical landscape has evolved markedly, with the Moving Average Convergence Divergence (MACD) indicator signalling bullish momentum on both weekly and monthly charts. This dual timeframe confirmation suggests sustained upward price movement potential. The MACD’s positive crossover on the weekly chart aligns with the stock’s recent breakout above its previous close of ₹1,639.90, reinforcing the bullish narrative.
Complementing this, the Relative Strength Index (RSI) presents a nuanced picture. While the weekly RSI remains neutral with no clear signal, the monthly RSI indicates bearishness, reflecting some caution over longer-term overbought conditions. This divergence suggests that while short-term momentum is strong, investors should monitor for potential pullbacks or consolidation phases.
Bollinger Bands further validate the bullish stance, with both weekly and monthly readings confirming upward price pressure. The stock’s intraday high of ₹1,850.95 nearly touched its 52-week high of ₹1,850.95, signalling strong buying interest and volatility expansion. Daily moving averages have also turned bullish, with the stock price comfortably trading above key averages, indicating positive short-term trend alignment.
Mixed Signals from Other Technical Indicators
The Know Sure Thing (KST) indicator presents a mixed scenario. While the weekly KST remains mildly bearish, the monthly KST has turned bullish, suggesting that longer-term momentum is improving despite short-term caution. This aligns with the Dow Theory’s bullish confirmation on both weekly and monthly timeframes, which supports the view of an ongoing primary uptrend.
On balance, the On-Balance Volume (OBV) indicator shows a mild bearish tone on the weekly chart but a mildly bullish stance monthly. This divergence in volume trends indicates that while recent trading volumes have been somewhat cautious, the overall accumulation over the longer term remains positive, a healthy sign for sustained price appreciation.
Price Performance Outpaces Benchmarks
Novartis India’s price appreciation has significantly outperformed the broader market benchmarks. Over the past week, the stock returned 15.07%, compared to the Sensex’s decline of 1.78%. This outperformance extends over longer periods, with a one-month return of 13.26% versus Sensex’s negative 3.72%, and a year-to-date gain of 134.06% against the Sensex’s 11.32% loss. Even on a one-year basis, Novartis India has surged 97.36%, while the Sensex fell 6.45%.
Over three, five, and ten-year horizons, the stock has delivered compounded returns of 144.76%, 119.83%, and 150.53% respectively, demonstrating consistent long-term growth despite sector volatility. These figures highlight Novartis India’s resilience and ability to generate alpha in a challenging market environment.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Mojo Score Upgrade Reflects Improved Outlook
Reflecting the positive technical developments, Novartis India’s MarketsMOJO score has improved to 71.0, earning a Buy grade as of 8 September 2026, upgraded from a previous Hold rating. This upgrade signals enhanced confidence in the stock’s near-term prospects, supported by a comprehensive assessment of price momentum, volume trends, and sector fundamentals.
The company remains classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which has been gaining investor attention due to favourable regulatory developments and innovation pipelines. The upgrade in technical trend from mildly bullish to bullish further corroborates the stock’s strengthening position within its industry peer group.
Key Moving Averages and Price Levels
On the daily chart, Novartis India’s price is trading well above its key moving averages, including the 50-day and 200-day simple moving averages, which act as dynamic support levels. The stock’s ability to hold above these averages after a strong rally is a positive technical sign, suggesting that the recent price surge is supported by genuine buying interest rather than speculative spikes.
The proximity to the 52-week high of ₹1,850.95 indicates that the stock is testing critical resistance levels. A sustained breakout above this level could trigger further upside momentum, attracting momentum traders and institutional investors alike. Conversely, any failure to breach this resistance may lead to short-term consolidation or profit-taking.
Sector and Market Context
The Pharmaceuticals & Biotechnology sector has experienced mixed performance recently, with regulatory uncertainties and global supply chain challenges impacting some players. However, Novartis India’s strong technical signals and robust returns relative to the Sensex suggest it is well-positioned to capitalise on sector tailwinds.
Investors should note that while the monthly RSI’s bearish signal advises caution, the overall technical framework remains constructive. The combination of bullish MACD, Bollinger Bands, and moving averages, alongside positive Dow Theory confirmation, provides a compelling case for continued upward momentum in the medium term.
Want to dive deeper on Novartis India Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Investor Takeaway
Novartis India Ltd’s recent technical parameter changes highlight a clear shift in market sentiment, with multiple indicators aligning to suggest a bullish momentum phase. The stock’s strong outperformance relative to the Sensex and its sector peers, combined with an upgraded Mojo Grade to Buy, make it an attractive proposition for investors seeking exposure to the Pharmaceuticals & Biotechnology space.
However, investors should remain mindful of the mixed signals from the monthly RSI and weekly KST, which counsel prudence and the possibility of short-term volatility. Monitoring key resistance levels near ₹1,850 and volume trends will be critical in assessing the sustainability of the current rally.
Overall, Novartis India’s technical profile supports a positive outlook, with the potential for further gains if the stock can maintain its momentum and break through near-term resistance. This makes it a compelling candidate for inclusion in portfolios focused on growth within the healthcare sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
